Room temperature stable solid vaccine formulations suitable for needle free delivery

适合无针注射的室温稳定固体疫苗制剂

• 批准号: 131068
• 金额: $ 19.11万
• 依托单位: GLIDE PHARMACEUTICAL TECHNOLOGIES LIMITED
• 依托单位国家: 英国
• 项目类别: Feasibility Studies
• 财政年份: 2013
• 资助国家: 英国
• 起止时间: 2013 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=131068
• 关键词: Room; temperature; stable; solid; vaccine

Needle free delivery of a room temperature stable vaccine which has the potential to reduce dosing frequency and / or to save antigen content has been a 'holy grail' of vaccine technology. Glide Pharma has developed a needle free device (recently completed a Phase 1 clinical study) that can deliver solid formulations and can uniquely meet all three requirements.Glide has previously demonstrated user acceptability and the dose sparing effect of the technology. The aim of this project is to evaluate room temperature stability which, theroretically, should be much easier to achieve with a solid vaccine compared to a liquid formulation.Glide can revolutionise vaccine delivery with its needle free, stable and low cost vaccine technology. This will enable developed countries to be better prepared for pandemic situations and to reduce healthcare costs, and the developing countries to enjoy the full benefits of modern vaccines.

无针递送室温稳定的疫苗，这种疫苗有可能减少给药频率和/或保存抗原含量，一直是疫苗技术的“圣杯”。Glide制药公司开发了一种无针装置（最近完成了一期临床研究），可以提供固体配方，并且可以独特地满足所有三个要求。Glide之前已经证明了该技术的用户可接受性和剂量节约效果。该项目的目的是评估室温稳定性，从理论上讲，固体疫苗比液体疫苗更容易实现室温稳定性。Glide可以通过其无针头、稳定和低成本的疫苗技术彻底改变疫苗交付。这将使发达国家能够更好地为流行病做好准备，并降低保健费用，使发展中国家能够充分享受现代疫苗的好处。